Anna Birnhuber

Dr. Anna Birnhuber

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ABAnna Birnhuber
Anna Birnhuber
EFElisabeth Fliesser
Elisabeth Fliesser
GGGregor Gorkiewicz
Gregor Gorkiewicz
MZMartin Zacharias
Martin Zacharias
BSBenjamin Seeliger
Benjamin Seeliger
Grazyna KwapiszewskaGrazyna Kwapiszewska
Grazyna Kwapiszewska
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current coronavirus disease (COVID-19) pandemic [1]. Over the last months, a plethora of novel research articles has been published, dealing with multiple aspects and manifestations of the disease. Increasing evidence points to a central role of endothelial cells (ECs) in SARS-CoV-2 infection [2–5]. Early studies have already indicated increased expression of vascular and inflammatory factors (such as VCAM-1, IL-8 or MCP-1) in COVID-19 lung tissue [2]. Such markers of endothelial dysfunction and altered endothelial cell integrity are important predictors of a poor outcome in SARS-CoV-2 infections [6], and they are associated with pulmonary edema, intravascular thrombosis and acute respiratory distress syndrome (ARDS).

15 August 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
IBIzabela Borek
Izabela Borek
ABAnna Birnhuber
Anna Birnhuber
NVNorbert F. Voelkel
Norbert F. Voelkel
LMLeigh Marsh
Leigh Marsh
Grazyna KwapiszewskaGrazyna Kwapiszewska
Grazyna Kwapiszewska
The pulmonary vasculature has been frequently overlooked in acute and chronic lung diseases, such as acute respiratory distress syndrome (ARDS), pulmonary fibrosis (PF), and chronic obstructive pulmonary disease (COPD). The primary emphasis in the management of these parenchymal disorders has largely revolved around the injury and aberrant repair of epithelial cells. However, there is increasing evidence that the vascular endothelium plays an active role in the development of acute and chronic lung diseases. The endothelial cell network in the capillary bed and the arterial and venous vessels provides a metabolically highly active barrier that controls the migration of immune cells, regulates vascular tone and permeability, and participates in the remodeling processes. Phenotypically and functionally altered endothelial cells, and remodeled vessels, can be found in acute and chronic lung diseases, although to different degrees, likely because of disease-specific mechanisms. Since vascular remodeling is associated with pulmonary hypertension, which worsens patient outcomes and survival, it is crucial to understand the underlying vascular alterations. In this Review, we describe the current knowledge regarding the role of the pulmonary vasculature in the development and progression of ARDS, PF, and COPD; we also outline future research directions with the hope of facilitating the development of mechanism-based therapies.

1 February 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MLMathias Loibl
Mathias Loibl
IKIsabella Klein
Isabella Klein
MPMichael Prattes
Michael Prattes
CSClaudia Schmidt
Claudia Schmidt
LKLisa Kappel
Lisa Kappel
HBHelmut Bergler
Helmut Bergler
The drug diazaborine is the only known inhibitor of ribosome biogenesis and specifically blocks large subunit formation in eukaryotic cells. However, the target of this drug and the mechanism of inhibition were unknown. Here we identify the AAA-ATPase Drg1 as a target of diazaborine. Inhibitor binding into the second AAA domain of Drg1 requires ATP loading and results in inhibition of ATP hydrolysis in this site. As a consequence the physiological activity of Drg1, i.e. the release of Rlp24 from pre-60S particles, is blocked, and further progression of cytoplasmic preribosome maturation is prevented. Our results identify the first target of an inhibitor of ribosome biogenesis and provide the mechanism of inhibition of a key step in large ribosomal subunit formation.

1 December 2019 in Cellular Signalling
Verified
Journal Article
Open access
ABAnna Birnhuber
Anna Birnhuber
VBV. Biasin
V. Biasin
DSD. Schnoegl
D. Schnoegl
LMLeigh Marsh
Leigh Marsh
Grazyna KwapiszewskaGrazyna Kwapiszewska
Grazyna Kwapiszewska
Fos-related antigen-2 (Fra-2) belongs to the activator protein 1 (AP-1) family of transcription factors and is involved in a broad variety of cellular processes, such as proliferation or differentiation. Aberrant expression of Fra-2 or regulation can lead to severe growth defects or diverse pathologies. Elevated Fra-2 expression has been described in several chronic lung diseases, such as pulmonary fibrosis, chronic obstructive pulmonary disease and asthma. However, the pathomechanisms behind the Fra-2-induced pulmonary remodelling are still not fully elucidated. Fra-2 overexpressing mice were initially described as a model of systemic sclerosis associated organ fibrosis, with predominant alterations in the lung. High levels of Fra-2 expression give rise to profound inflammation with severe remodelling of the parenchyma and the vasculature, resulting in fibrosis and pulmonary hypertension, respectively, but also alters bronchial function. In this review we discuss the central role of Fra-2 connecting inflammation, cellular proliferation and extracellular matrix deposition underlying chronic lung diseases and what we can learn for future therapeutic options.

30 August 2018 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
GKGrazyna Kwapiszewska
Grazyna Kwapiszewska
ABAnna Birnhuber
Anna Birnhuber
JWJochen Wilhelm
Jochen Wilhelm
LMLeigh Marsh
Leigh Marsh
HPHelene Thekkekara Puthenparampil
Helene Thekkekara Puthenparampil
MWMalgorzata Wygrecka
Malgorzata Wygrecka
Despite the beneficial effects of pirfenidone in treating idiopathic pulmonary fibrosis (IPF), it remains unclear if lung fibroblasts (FB) are the main therapeutic target.To resolve this question, we employed a comparative transcriptomic approach and analysed lung homogenates (LH) and FB derived from IPF patients treated with or without pirfenidone.In FB, pirfenidone therapy predominantly affected growth and cell division pathways, indicating a major cellular metabolic shift. In LH samples, pirfenidone treatment was mostly associated with inflammation-related processes. In FB and LH, regulated genes were over-represented in the Gene Ontology node “extracellular matrix”. We identified lower expression of cell migration-inducing and hyaluronan-binding protein (CEMIP) in both LH and FB from pirfenidone-treated IPF patients. Plasma levels of CEMIP were elevated in IPF patients compared to healthy controls and decreased after 7 months of pirfenidone treatment. CEMIP expression in FB was downregulated in a glioma-associated oncogene homologue-dependent manner and CEMIP silencing in IPF FB reduced collagen production and attenuated cell proliferation and migration.Cumulatively, our approach indicates that pirfenidone exerts beneficial effectsviaits action on multiple pathways in both FB and other pulmonary cells, through its ability to control extracellular matrix architecture and inflammatory reactions.

7 February 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
MWMalgorzata Wygrecka
Malgorzata Wygrecka
ABAnna Birnhuber
Anna Birnhuber
BSBenjamin Seeliger
Benjamin Seeliger
LMLaura Michalick
Laura Michalick
OPOleg Pak
Oleg Pak
KPKlaus T. Preissner
Klaus T. Preissner
The high incidence of thrombotic events suggests a possible role of the contact system pathway in COVID-19 pathology. In this study, we determined the altered levels of factor XII (FXII) and its activation products in critically ill patients with COVID-19 in comparison with patients with severe acute respiratory distress syndrome related to the influenza virus (acute respiratory distress syndrome [ARDS]-influenza). Compatible with those data, we found rapid consumption of FXII in COVID-19 but not in ARDS-influenza plasma. Interestingly, the lag phase in fibrin formation, triggered by the FXII activator kaolin, was not prolonged in COVID-19, as opposed to that in ARDS-influenza. Confocal and electron microscopy showed that increased FXII activation rate, in conjunction with elevated fibrinogen levels, triggered formation of fibrinolysis-resistant, compact clots with thin fibers and small pores in COVID-19. Accordingly, clot lysis was markedly impaired in COVID-19 as opposed to that in ARDS-influenza. Dysregulated fibrinolytic system, as evidenced by elevated levels of thrombin-activatable fibrinolysis inhibitor, tissue-plasminogen activator, and plasminogen activator inhibitor-1 in COVID-19 potentiated this effect. Analysis of lung tissue sections revealed widespread extra- and intravascular compact fibrin deposits in patients with COVID-19. A compact fibrin network structure and dysregulated fibrinolysis may collectively contribute to a high incidence of thrombotic events in COVID-19.